MedTrace Logo

D-Serine Treatment For Tardive Dyskinesia

NCT01804920 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-10-11

No results posted yet for this study

Summary

Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which are caused by treatment with presently used antipsychotics drugs.

The hypothesis under investigation in the present study is that D-serine adjuvant treatment may improve TD in schizophrenia patients diagnosed with this disorder.

Conditions

  • Schizophrenia and Schizoaffective Disorder
  • Tardive Dyskinesia

Interventions

DIETARY_SUPPLEMENT

D-serine

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Uriel Heresco-Levy, MD · Herzog Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01804920 on ClinicalTrials.gov